Paul R. Cheney, MD, PhD; Susan E. Dorman; David S. Bell, MD
This content is PDF only. Please click on the PDF icon to access.
To the editor: The chronic fatigue syndrome (the chronic mononucleosis syndrome, the chronic Epstein-Barr virus syndrome) is a recently described illness with numerous symptoms of unknown cause (1, 2). Abnormalities of natural killer function and decreased enhancement of cytotoxicity in the presence of interleukin-2 have been found (3). The results of recent studies (4) of cancer treatment with recombinant interleukin-2 alone and in combination with autologous lymphokine-activated killer cells have documented side effects that superficially resemble manifestations of the chronic fatigue syndrome. For this reason, we undertook a preliminary study of interleukin-2 plasma levels in two geographically separate groups of
Cheney PR, Dorman SE, Bell DS. Interleukin-2 and the Chronic Fatigue Syndrome. Ann Intern Med. 1989;110:321. doi: 10.7326/0003-4819-110-4-321_1
Download citation file:
Published: Ann Intern Med. 1989;110(4):321.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use